ScholarLens Back to search
2010•Leukemia & lymphoma/Leukemia and lymphomaOpen access

The efficacy and stem cell toxicity of cladribine and rituximab in the treatment of patients with chronic lymphocytic leukemia: are all purine analogs created equal?

Tamar Tadmor, Aaron Polliack, Constantine S. Tam

Open full text 0 citations

Abstract

Large single-institution studies and randomized trials have shown that the most effective regimens in the treatment of chronic lymphocytic leukemia (CLL) are chemo-immunotherapy protocols combining...

Open-access reader

About this research paper

What this paper is about

Large single-institution studies and randomized trials have shown that the most effective regimens in the treatment of chronic lymphocytic leukemia (CLL) are chemo-immunotherapy protocols combining...

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Large single-institution studies and randomized trials have shown that the most effective regimens in the treatment of chronic lymphocytic leukemia (CLL) are chemo-immunotherapy protocols combining...

Key concepts: Cladribine, Pentostatin, Fludarabine, Chronic lymphocytic leukemia, Medicine, Purine analogue, Rituximab, Hairy cell leukemia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The efficacy and stem cell toxicity of cladribine and rituximab in the treatment of patients with chronic lymphocytic leukemia: are all purine analogs created equal? — Research Paper | ScholarLens